September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
AMD and glaucoma proteomics: Insights to mechanisms and biomarkers
Author Affiliations & Notes
  • John W Crabb
    Cleveland Clinic, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   John Crabb, US Patent 7,341,839 B2 (P)
  • Footnotes
    Support  NIH Grants EY14239, EY14240, EY15638, EY018147, EY21840, EY022134, EY011610, Ohio Biomedical Research and Technology Transfer (BRTT) Grant 05-29, a Challenge Grant from Research to Prevent Blindness (RPB), an RPB Senior Investigator Award, the Foundation Fighting Blindness, Legacy Good Samaritan Foundation, and the Cleveland Clinic Foundation
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John W Crabb; AMD and glaucoma proteomics: Insights to mechanisms and biomarkers. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Proteomic research approaches are increasingly providing new molecular insights to ocular diseases. A defining advantage of proteomics is the capability to identify and quantify thousands of proteins without prespecification of analytes. Proteomic contributions will be presented to current understandings of AMD and glaucoma pathologies and the identification of potentially useful biomarkers. For AMD, focus will be upon proteomic studies of drusen and lipofuscin, oxidative modifications in AMD ocular tissues and plasma and quantitative analyses of macular Bruch’s membrane/choroid with AMD progression and category. For glaucoma, emphasis will be on recent global quantitative analyses of optic nerve head, orbital optic nerve, retina and peripapillary sclera from monkeys with laser-induced, unilateral early experimental glaucoma (EG) that have revealed significantly altered proteins at high IOP EG and suggest major proteomic differences between high IOP and mild IOP EG.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.